login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ONCOLYTICS BIOTECH INC (ONCY) Stock News
USA
-
Nasdaq
- NASDAQ:ONCY -
CA6823108759
-
Common Stock
1
USD
+0.01 (+0.86%)
Last: 11/21/2025, 8:00:02 PM
1.03
USD
+0.03 (+3%)
After Hours:
11/21/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ONCY Latest News, Press Relases and Analysis
All
Press Releases
3 days ago - By: Oncolytics Biotech Inc.
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders
4 days ago - By: Zacks Investment Research
All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy
4 days ago - By: FN Media Group LLC
- Mentions:
ALXO
ERAS
IMRX
PRLD
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
4 days ago - By: Oncolytics Biotech Inc.
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer
19 days ago - By: Oncolytics Biotech® Inc.
Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy
26 days ago - By: Oncolytics Biotech® Inc.
Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care
a month ago - By: Oncolytics Biotech® Inc.
Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada
a month ago - By: Benzinga
- Mentions:
IVA
ARAY
KIDS
VNRX
...
12 Health Care Stocks Moving In Friday's Pre-Market Session
2 months ago - By: Oncolytics Biotech® Inc.
Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
2 months ago - By: Oncolytics Biotech® Inc.
Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
2 months ago - By: Benzinga
- Mentions:
AHG
COCP
CHEK
HSDT
...
12 Health Care Stocks Moving In Monday's Pre-Market Session
3 months ago - By: Oncolytics Biotech® Inc.
Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions
3 months ago - By: Oncolytics Biotech® Inc.
Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors
3 months ago - By: Oncolytics Biotech® Inc.
Oncolytics Biotech® Announces Upcoming Investor Conferences in September
3 months ago - By: Oncolytics Biotech® Inc.
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
4 months ago - By: Oncolytics Biotech® Inc.
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
4 months ago - By: Oncolytics Biotech® Inc.
Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
Please enable JavaScript to continue using this application.